Recently Completed Clinical Trial Indicates that DILIsym Backup Compound Predictions Were Correct

• DILIsym simulations suggested that the backup compound is considerably less likely to pose a DILI risk than the lead compound at the proposed clinical dosing regimens
• No liver signals reported for any dosing regimes for the backup compound in clinical trial completed in 2018
• Combination of predicted and measured safety have enabled sponsor to confidently continue clinical development of the backup compound